s6y

Scienture Holdings, Inc.

Ticker
SCNX
CIK
1382574
Industry
Pharmaceutical Preparations
Formerly
TRxADE HEALTH, INC, TRXADE GROUP, INC., XCELLINK INTERNATIONAL INC., Bluebird Exploration Co.

Financials 78

  1. 10-Q Quarterly Report for period ending Sep 30, 2026
  2. 10-Q Quarterly Report for period ending Jun 30, 2026
  3. 10-Q Quarterly Report for period ending Mar 31, 2026
  4. 10-K/A Annual Report for period ending Dec 31, 2025
  5. 10-K Annual Report for period ending Dec 31, 2025
  6. 10-Q Quarterly Report for period ending Sep 30, 2025
  7. 10-Q Quarterly Report for period ending Jun 30, 2025
  8. 10-Q Quarterly Report for period ending Mar 31, 2025
  9. 10-K Annual Report for period ending Dec 31, 2024
  10. 10-Q Quarterly Report for period ending Sep 30, 2024

All 78 financials filings

News 167

  1. 8-K Current report filing
  2. 8-K Current report filing
  3. 8-K Current report filing
  4. 8-K Current report filing
  5. 8-K Current report filing
  6. 8-K Current report filing
  7. 8-K Current report filing
  8. 8-K Current report filing
  9. 8-K Current report filing
  10. 8-K Current report filing

All 167 news filings

Ownership 87

  1. 5 Annual statement of changes in beneficial ownership of securities
  2. 3 Initial statement of beneficial ownership of securities
  3. 4 Statement of changes in beneficial ownership of securities
  4. 4 Statement of changes in beneficial ownership of securities
  5. 3 Initial statement of beneficial ownership of securities
  6. 3 Initial statement of beneficial ownership of securities
  7. 4/A Statement of changes in beneficial ownership of securities
  8. 4/A Statement of changes in beneficial ownership of securities
  9. SC 13G/A Major Shareholders
  10. 4 Statement of changes in beneficial ownership of securities

All 87 ownership filings

Prospectus 48

  1. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  2. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  3. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  4. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  5. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  6. S-3 Registration statement for specified transactions by certain issuers
  7. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  8. DRS Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy
  9. S-3 Registration statement for specified transactions by certain issuers
  10. 1-A-W Withdrawal of offering statement under Regulation A

All 48 prospectus filings

Proxies 41

  1. DEF 14A Definitive proxy statements
  2. PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition
  3. DEF 14A Definitive proxy statements
  4. PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition
  5. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  6. DEF 14A Definitive proxy statements
  7. DEF 14C Definitive information statements
  8. PRE 14C Preliminary information statement not related to a contested matter or merger/acquisition
  9. DEF 14C Definitive information statements
  10. PRE 14C Preliminary information statement not related to a contested matter or merger/acquisition

All 41 proxies filings

Other 88

  1. SCHEDULE 13G/A
  2. EFFECT Notice of Effectiveness
  3. CORRESP A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
  4. SCHEDULE 13G
  5. SCHEDULE 13G
  6. UPLOAD Letter (PDF)
  7. EFFECT Notice of Effectiveness
  8. CORRESP A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
  9. UPLOAD Letter (PDF)
  10. D/A Exempt (Private) Offering

All 88 other filings